260 related articles for article (PubMed ID: 18471159)
1. Empiric vs. preemptive antifungal treatment: an appraisal of treatment strategies in haematological patients.
Rieger CT; Ostermann H
Mycoses; 2008; 51 Suppl 1():31-4. PubMed ID: 18471159
[TBL] [Abstract][Full Text] [Related]
2. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M
Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327
[TBL] [Abstract][Full Text] [Related]
3. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.
Maertens J; Theunissen K; Verhoef G; Verschakelen J; Lagrou K; Verbeken E; Wilmer A; Verhaegen J; Boogaerts M; Van Eldere J
Clin Infect Dis; 2005 Nov; 41(9):1242-50. PubMed ID: 16206097
[TBL] [Abstract][Full Text] [Related]
4. [Antimicrobial prophylaxis and therapy in neutropenia].
Link H
Mycoses; 2003; 46 Suppl 2():21-32. PubMed ID: 15055140
[TBL] [Abstract][Full Text] [Related]
5. Wait and see or rush and switch? New questions for the management of patients with febrile neutropenia receiving antifungal prophylaxis.
Karthaus M; Hentrich M
Mycoses; 2011 Jan; 54 Suppl 1():1-6. PubMed ID: 21126265
[TBL] [Abstract][Full Text] [Related]
6. Prevention and treatment of invasive fungal diseases in neutropenic patients.
Almyroudis NG; Segal BH
Curr Opin Infect Dis; 2009 Aug; 22(4):385-93. PubMed ID: 19506476
[TBL] [Abstract][Full Text] [Related]
7. European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies.
Hoenigl M; Strenger V; Buzina W; Valentin T; Koidl C; Wölfler A; Seeber K; Valentin A; Strohmeier AT; Zollner-Schwetz I; Raggam RB; Urban C; Lass-Flörl C; Linkesch W; Krause R
J Antimicrob Chemother; 2012 Aug; 67(8):2029-33. PubMed ID: 22566591
[TBL] [Abstract][Full Text] [Related]
8. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts.
Segal BH; Almyroudis NG; Battiwalla M; Herbrecht R; Perfect JR; Walsh TJ; Wingard JR
Clin Infect Dis; 2007 Feb; 44(3):402-9. PubMed ID: 17205448
[TBL] [Abstract][Full Text] [Related]
9. Antifungal treatment strategies in high risk patients.
Rüping MJ; Vehreschild JJ; Cornely OA
Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331
[TBL] [Abstract][Full Text] [Related]
10. [Prophylaxis and treatment of invasive fungal infection in neutropenic patients].
Vallejo C; Rovira M
Rev Esp Quimioter; 2010 Dec; 23(4):177-83. PubMed ID: 21191555
[TBL] [Abstract][Full Text] [Related]
11. Invasive fungal infections: epidemiology and analysis of antifungal prescriptions in onco-haematology.
des Champs-Bro B; Leroy-Cotteau A; Mazingue F; Pasquier F; François N; Corm S; Lemaitre L; Poulain D; Yakoub-Agha I; Alfandari S; Sendid B
J Clin Pharm Ther; 2011 Apr; 36(2):152-60. PubMed ID: 21366643
[TBL] [Abstract][Full Text] [Related]
12. Empirical antifungal therapy in febrile neutropenic patients: current status.
Kibbler CC
Curr Top Med Mycol; 1997 Dec; 8(1-2):5-14. PubMed ID: 9504062
[TBL] [Abstract][Full Text] [Related]
13. Advances in antifungal prophylaxis and empiric therapy in patients with hematologic malignancies.
Murali S; Langston A
Transpl Infect Dis; 2009 Dec; 11(6):480-90. PubMed ID: 19725908
[TBL] [Abstract][Full Text] [Related]
14. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.
Maertens J
Eur J Haematol; 2007 Apr; 78(4):275-82. PubMed ID: 17241370
[TBL] [Abstract][Full Text] [Related]
15. Empirical antifungal therapy in selected patients with persistent febrile neutropenia.
Aguilar-Guisado M; Espigado I; Cordero E; Noguer M; Parody R; Pachón J; Cisneros JM
Bone Marrow Transplant; 2010 Jan; 45(1):159-64. PubMed ID: 19525983
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy.
Cornely OA; Aversa F; Cook P; Jones B; Michallet M; Shea T; Vallejo C
Eur J Haematol; 2011 Oct; 87(4):289-301. PubMed ID: 21752098
[TBL] [Abstract][Full Text] [Related]
17. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation.
Michallet M; Ito JI
J Clin Oncol; 2009 Jul; 27(20):3398-409. PubMed ID: 19487382
[TBL] [Abstract][Full Text] [Related]
18. Treatment of invasive fungal infections in high-risk haematological patients: what have we learnt in the past 10 years?
Vallejo C; Vázquez L; Cabrera Martín JR; Carreras E; García Rodríguez J; Ruiz Camps I; Fortún J; Mensa J; Barberán J
Rev Esp Quimioter; 2013 Dec; 26(4):378-86. PubMed ID: 24399355
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders.
Yoshida M; Tamura K; Imamura M; Niitsu Y; Sasaki T; Urabe A; Ohyashiki K; Naoe T; Kanamaru A; Tanimoto M; Masaoka T
Ann Hematol; 2012 Mar; 91(3):449-57. PubMed ID: 21894476
[TBL] [Abstract][Full Text] [Related]
20. New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies.
Leather HL; Wingard JR
Blood Rev; 2006 Sep; 20(5):267-87. PubMed ID: 16781028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
